Welcome to our dedicated page for Opthea American Depositary Shares news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea American Depositary Shares stock.
Opthea Limited (symbol: OPT) is a pioneering Australian biotechnology company dedicated to developing innovative biologic therapies for eye diseases. With a strong focus on medical technology and healthcare, Opthea's primary mission is to address unmet medical needs through advanced therapeutic solutions.
Opthea's flagship product, OPT-302, is a groundbreaking biologic treatment designed to inhibit VEGF-C and VEGF-D, which are critical factors in abnormal blood vessel growth and leakage. These mechanisms are commonly associated with eye conditions such as wet age-related macular degeneration (wet AMD). Currently, OPT-302 is undergoing a Phase 1/2a clinical trial to evaluate its safety and efficacy in patients suffering from wet AMD, marking a significant milestone in the company's development pipeline.
The company's robust intellectual property portfolio underpins its research and development efforts, covering essential targets like VEGF-C, VEGF-D, and VEGF Receptor-3. These assets form the foundation of Opthea's strategy to develop advanced treatments aimed at reducing vascular leakage and managing diseases linked to blood and lymphatic vessel growth.
Recent achievements underscore Opthea's commitment to advancing its clinical programs. The company has launched a fully underwritten Retail Entitlement Offer, inviting eligible retail shareholders in Australia and New Zealand to participate. This initiative is part of Opthea's broader strategy to secure funding and support the continued development of OPT-302.
Participants in the Placement and Entitlement Offer will receive new options, each exercisable at A$0.80, set to expire on 31 August 2025. These options are expected to be quoted on the ASX, providing additional investment opportunities for shareholders.
Investment in biotechnology firms like Opthea entails inherent risks, including the lengthy clinical trial process, patent protection uncertainties, and rapid technological advancements. However, Opthea's focused approach and strategic partnerships position it as a promising player in the biotech space. For detailed information on participation and investment opportunities, refer to the Prospectus available on the ASX website and Opthea's official site.
For more updates and information, investors and media can contact:
Media: Hershel Berry (hberry@bplifescience.com)
Investor: PJ Kelleher (pkelleher@lifesciadvisors.com)
Opthea Limited (ASX:OPT; Nasdaq:OPT) has received a Chinese patent for its molecule OPT-302, aimed at treating retinal diseases like wet AMD and diabetic macular edema. This patent, granted in the name of its subsidiary Vegenics Pty Limited, extends patent protection to February 2034. OPT-302 is currently being evaluated in two Phase 3 trials, ShORE and COAST. The patent supports commercialization plans in China, a key market due to its growing biologics sector and the efficacy shown in clinical studies.
Opthea Limited has commenced patient enrollment at the first clinical trial sites in the Asia-Pacific for the OPT-302 Phase 3 program, targeting wet age-related macular degeneration (AMD). This milestone follows successful patient recruitment in the U.S., Canada, and Europe. The ShORe and COAST trials aim to assess the efficacy of OPT-302 in combination with existing therapies, with results expected by late 2023. The FDA has granted Fast Track status to OPT-302, facilitating quicker development for this unmet medical need.
Opthea Limited (ASX:OPT; Nasdaq:OPT) has opened enrollment for its Phase 3 clinical trials of OPT-302 in Europe, targeting wet age-related macular degeneration (AMD). The ShORe and COAST trials aim to enroll approximately 990 patients each and assess OPT-302's efficacy in combination with existing therapies. The FDA has granted OPT-302 Fast Track designation, facilitating expedited development. Top-line data is expected in late 2023, with plans for regulatory submissions to the FDA and EMA to follow. This expansion highlights Opthea's commitment to addressing retinal diseases globally.
Opthea Limited (ASX:OPT) announced that CEO Dr. Megan Baldwin will participate in three investor conferences in September 2021. These events include Citi's 16th Annual BioPharma Virtual Conference on September 9, H.C. Wainwright Annual Healthcare Conference on September 13, and Oppenheimer Healthcare Fall Summit on September 20. Opthea is focused on developing therapies for retinal diseases, particularly its lead product candidate, OPT-302, currently in Phase 3 trials. The firm emphasizes the speculative nature of biotech investments due to various inherent risks.
Opthea Limited (ASX:OPT; Nasdaq:OPT) has made significant strides in advancing its lead product OPT-302 for wet age-related macular degeneration (AMD). The company reported the treatment of its first patient in Phase 3 trials (ShORe and COAST) and received FDA Fast Track designation, expediting its development. Opthea's cash reserves stand at US$118.2 million, with R&D expenses increasing to US$25.9 million due to ongoing trials. Notably, the fiscal year ended June 30, 2021, resulted in a net loss of US$45.3 million, up from US$11.1 million the previous year.
Opthea Limited (ASX:OPT), a biopharmaceutical company focused on retinal diseases, announced that CEO Dr. Megan Baldwin will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be available on-demand starting at 7:00 AM ET. Opthea is developing OPT-302, a leading product candidate in Phase 3 trials aimed at treating conditions like wet age-related macular degeneration and diabetic macular edema. The company emphasizes the inherent risks associated with biotechnology investments and advises seeking professional investment advice.
Opthea Limited (ASX:OPT; Nasdaq:OPT) has commenced patient recruitment in Canada for its Phase 3 clinical trials of OPT-302, aimed at treating wet age-related macular degeneration (AMD). Following Health Canada's approval, the ShORe and COAST trials will evaluate the efficacy of OPT-302 alongside existing therapies. The FDA has awarded OPT-302 Fast Track status due to positive previous trial outcomes, which could accelerate its approval process. Results from these trials are expected in the second half of 2023, potentially leading to global marketing authorizations.
Opthea Limited (ASX:OPT; Nasdaq:OPT) announced that the FDA granted Fast Track designation for its VEGF-C/-D trap inhibitor, OPT-302, aimed at treating neovascular (wet) age-related macular degeneration (AMD). This designation facilitates expedited clinical development, allowing for more frequent communications with the FDA and a Rolling Review of the Biologic Drug Application. OPT-302 holds potential as a differentiated treatment option, possibly improving vision outcomes for patients with unresolved responses to traditional therapies.
Opthea Limited (ASX:OPT; Nasdaq:OPT) announced the appointment of Mrs. Karen Adams as Vice President of Finance and Company Secretary, effective June 12, 2021. With extensive experience in finance, including her role as Chief Financial Officer at Victor Smorgon Group and prior experience at Nexvet Biopharma, Mrs. Adams brings valuable expertise in corporate governance and financial reporting. This leadership change occurs as Opthea advances its product OPT-302 through pivotal Phase 3 clinical trials for wet age-related macular degeneration, marking a significant phase in the company's growth.
Opthea Limited (ASX:OPT; Nasdaq:OPT) has appointed Dr. Julia Haller and Ms. Judith Robertson as independent Non-Executive Directors as of June 1, 2021. Their extensive backgrounds in ophthalmology and commercial life sciences aim to enhance Opthea's clinical and commercialization strategies. The company is focused on advancing its lead product candidate, OPT-302, which is undergoing pivotal Phase 3 trials for wet age-related macular degeneration (AMD), with top-line data expected in 2023. The new board members are expected to provide significant expertise in navigating these developments.
FAQ
What is the current stock price of Opthea American Depositary Shares (OPT)?
What is the market cap of Opthea American Depositary Shares (OPT)?
What does Opthea Limited specialize in?
What is OPT-302?
What stage is OPT-302 currently in?
How does Opthea fund its clinical programs?
What is the significance of VEGF-C and VEGF-D in Opthea's research?
How can investors participate in Opthea's funding offers?
What risks are associated with investing in Opthea?
Where can I find more information about Opthea’s developments?
Who can I contact for media inquiries about Opthea?
Who can I contact for investor inquiries about Opthea?
